PCIBO Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PCI Biotech Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 1.92 |
| 52 Week High | NOK 5.50 |
| 52 Week Low | NOK 1.92 |
| Beta | 1.89 |
| 1 Month Change | 0% |
| 3 Month Change | -5.65% |
| 1 Year Change | n/a |
| 3 Year Change | -97.17% |
| 5 Year Change | -91.58% |
| Change since IPO | -92.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| PCIBO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 9.4% | 3.3% |
| 1Y | n/a | -18.1% | 10.6% |
Return vs Industry: Insufficient data to determine how PCIBO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how PCIBO performed against the UK Market.
Price Volatility
| PCIBO volatility | |
|---|---|
| PCIBO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PCIBO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PCIBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 14 | Ronny Skuggedal | www.pcibiotech.com |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin.
PCI Biotech Holding ASA Fundamentals Summary
| PCIBO fundamental statistics | |
|---|---|
| Market cap | NOK 80.25m |
| Earnings (TTM) | -NOK 73.45m |
| Revenue (TTM) | NOK 4.75m |
16.9x
P/S Ratio-1.1x
P/E RatioIs PCIBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCIBO income statement (TTM) | |
|---|---|
| Revenue | NOK 4.75m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 4.75m |
| Other Expenses | NOK 78.20m |
| Earnings | -NOK 73.45m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 17, 2023
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,545.91% |
| Debt/Equity Ratio | 0% |
How did PCIBO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/06 13:32 |
| End of Day Share Price | 2022/09/08 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PCI Biotech Holding ASA is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bohn | Beringer Finance AB |